Evidence map›Paper›PMID 37600776›Full record

ArticleFrontiers in immunology2023

Influenza breakthrough infection in vaccinated mice is characterized by non-pathological lung eosinophilia.

Lauren A Chang, Angela Choi, Raveen Rathnasinghe, Prajakta Warang, Moataz Noureddine, Sonia Jangra, Yong Chen, Bruno G De Geest, Michael Schotsaert

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Lauren A ChangDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Angela ChoiDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Raveen RathnasingheDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Prajakta WarangDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Moataz NoureddineDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Sonia JangraDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Yong ChenDepartment of Pharmaceutics, Ghent University, Ghent, Belgium.
Bruno G De GeestDepartment of Pharmaceutics, Ghent University, Ghent, Belgium.
Michael SchotsaertDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Icahn School of Medicine at Mount Sinai · USGhent University · BE

Funding

COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4M
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6M
TRAINING PROGRAM: MECHANISMS OF VIRUS-HOST INTERACTIONST32AI007647 · NIAID · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI Domenico Tortorella · 2000 to 2026
$11.5M
7HP349, an oral integrin activator to augment effectiveness of pre-exposure influenza vaccinationR44AI176894 · NIAID · 7 HILLS PHARMA, LLC · PI DE, SIDDHARTHA, MARATHI, UPENDRA · 2023 to 2024
$1.9M
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunityR21AI176069 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SCHOTSAERT, MICHAEL, WONG, PAMELA TINMOI · 2023 to 2024
$466k
A Miniature Pig Model for the Study of Host-Immune Responses Against Influenza A VirusR21AI151229 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI RICHT, JUERGEN A, SCHOTSAERT, MICHAEL · 2020 to 2021
$457k
NIAID NIH HHS 75N93019C00051NIAID NIH HHS 75N93021C00014NIAID NIH HHS R21 AI151229NIAID NIH HHS R21 AI176069NIAID NIH HHS R44 AI176894NIAID NIH HHS T32 AI007647
6 · The paper itself

Abstract

Eosinophils are important mediators of mucosal tissue homeostasis, anti-helminth responses, and allergy. Lung eosinophilia has previously been linked to aberrant Type 2-skewed T cell responses to respiratory viral infection and may also be a consequence of vaccine-associated enhanced respiratory disease (VAERD), particularly in the case of respiratory syncytial virus (RSV) and the formalin-inactivated RSV vaccine. We previously reported a dose-dependent recruitment of eosinophils to the lungs of mice vaccinated with alum-adjuvanted trivalent inactivated influenza vaccine (TIV) following a sublethal, vaccine-matched H1N1 (A/New Caledonia/20/1999; NC99) influenza challenge. Given the differential role of eosinophil subset on immune function, we conducted the investigations herein to phenotype the lung eosinophils observed in our model of influenza breakthrough infection. Here, we demonstrate that eosinophil influx into the lungs of vaccinated mice is adjuvant- and sex-independent, and only present after vaccine-matched sublethal influenza challenge but not in mock-challenged mice. Furthermore, vaccinated and challenged mice had a compositional shift towards more inflammatory eosinophils (iEos) compared to resident eosinophils (rEos), resembling the shift observed in ovalbumin (OVA)-sensitized allergic control mice, however without any evidence of enhanced morbidity or aberrant inflammation in lung cytokine/chemokine signatures. Furthermore, we saw a lung eosinophil influx in the context of a vaccine-mismatched challenge. Additional layers of heterogeneity in the eosinophil compartment were observed via unsupervised clustering analysis of flow cytometry data. Our collective findings are a starting point for more in-depth phenotypic and functional characterization of lung eosinophil subsets in the context of vaccine- and infection-induced immunity.

Indexed as

AsthmaHypersensitivityInfluenza A Virus, H1N1 SubtypeInfluenza, HumanInfluenza VaccinesPulmonary EosinophiliaAnimalsBreakthrough InfectionsLungMiceInfluenza Vaccinesbreakthrough infectioneosinophils - immunologyeosinophils subtypesinfluenzainfluenza vaccination

Identifiers

PMID37600776
PMCPMC10437116
OpenAlexW4385575466

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.